Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease
about
Clinical development of gene therapy: results and lessons from recent successesNew approaches to the treatment of orphan genetic disorders: Mitigating molecular pathologies using chemicalsGene therapy for lower urinary tract dysfunctionCatecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disordersSynthetic biology and therapeutic strategies for the degenerating brain: Synthetic biology approaches can transform classical cell and gene therapies, to provide new cures for neurodegenerative diseasesParkinson's disease gene therapy: success by design meets failure by efficacyGene-based therapy of Parkinson's Disease: Translation from animal model to human clinical trial employing convection enhanced deliveryTreating Parkinson's disease in the 21st century: can stem cell transplantation compete?Adeno-associated virus-mediated cancer gene therapy: current statusCarbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned ratsSAFETY AND TOLERABILITY OF MRI-GUIDED INFUSION OF AAV2-hAADC INTO THE MID-BRAIN OF NON-HUMAN PRIMATE.Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis IClinical applications involving CNS gene transfer.Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.A GLP-Compliant Toxicology and Biodistribution Study: Systemic Delivery of an rAAV9 Vector for the Treatment of Mucopolysaccharidosis IIIB.Basic FGF or VEGF gene therapy corrects insufficiency in the intrinsic healing capacity of tendons.Focusing brain therapeutic interventions in space and time for Parkinson's disease.Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease.Recent advances in RNA interference therapeutics for CNS diseases.Convection-enhanced delivery improves distribution and efficacy of tumor-selective retroviral replicating vectors in a rodent brain tumor modelTranscriptional activity of novel ALDH1L1 promoters in the rat brain following AAV vector-mediated gene transferWidespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis.A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.Gene therapy for Parkinson's disease: state-of-the-art treatments for neurodegenerative disease.Gene therapy for the neurological manifestations in lysosomal storage disorders.Advances in non-dopaminergic treatments for Parkinson's diseasePreclinical toxicity evaluation of AAV for pain: evidence from human AAV studies and from the pharmacology of analgesic drugs.Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.Gene therapy for Parkinson's disease: still a hot topic?Gene therapy research in Asia.Gene therapy for neurological disorders.Perspective on the Road toward Gene Therapy for Parkinson's Disease.Viral vectors for therapy of neurologic diseases.Preclinical study of rAAV2-sTRAIL: pharmaceutical efficacy, biodistribution and safety in animals.Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease.Neurotransmitter release: vacuolar ATPase V0 sector c-subunits in possible gene or cell therapies for Parkinson's, Alzheimer's, and psychiatric diseases.Adeno-Associated Virus-Based Gene Therapy for CNS Diseases.Therapies for Parkinson's diseases: alternatives to current pharmacological interventions.Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.Gene therapy approaches in the non-human primate model of Parkinson's disease.
P2860
Q26743393-8A03EF4B-4187-411A-8FB7-C8DC864B1CCFQ26801582-F360818A-4DF6-4473-B7DC-5C06838B7158Q26824783-A10562B6-E0B0-4961-B6DC-DD33BCF5CA9AQ26826093-8099347D-C733-47DA-B4BB-5D50DE3D19EAQ26830610-9FB2FF09-21F3-4D72-BF99-A9ED2ECC768AQ26851325-633EDE95-F214-42F5-9296-BA542353DC5EQ26851517-8278530C-3191-4A0C-8B4C-339FCF076053Q27024152-16C3AF19-892E-4B5C-A68F-2EF70F57390AQ27026177-EA531FFF-9FBA-4B8B-BBB2-C121B6DBAAF5Q27310170-EE0C4B27-8798-4753-A8AE-B1723B71F3ADQ34762396-DEFAB91E-28E0-4120-9A8C-4D952BD32D9EQ35600310-F719502C-658B-49FC-A938-349610B6BF7DQ35899850-372155F1-2F4A-44F7-B96C-78A8E1BA589BQ36271585-2EB283AF-7A9B-4C11-8E92-E329801D674CQ36521756-C45A7990-205D-4FF9-A7F9-45FC5AE02A99Q36569445-7B5F1EA2-83DB-4DD3-AFB0-C8DF832B8AE4Q36745293-FC992F83-C5E3-47D1-83C2-036364BFA7F7Q36925905-D714AFFD-B27B-4F4C-A251-B401E296FF3AQ36983193-081AC976-F7FA-427B-9322-E327AFCB4402Q37069887-412DE31D-7D0E-4CD7-A03D-193A5CF2EC06Q37458119-D1BBCD63-7EB2-4A4D-9B36-8C33D8AD4B82Q37463967-53DA58D2-DFFA-4DE2-AFD0-788740B46863Q38075068-DAE30EDC-1217-4B95-A09F-06166BCFEAC0Q38112216-891394C7-92D3-47F2-932B-6A3E89BC4E84Q38200599-E20E7062-A80B-4C70-A6BB-CCC48FB8B1EAQ38218083-B8A0B0A7-7E35-43F1-96A7-97F828A58D20Q38245677-983EAAF7-CBD6-4A25-9979-5EE305ADDFBFQ38275513-FE5EF974-63BA-4AD5-9BA8-1955C37A1915Q38284287-0A430743-689E-4B54-8182-AA022258EFF5Q38654544-7DEB0C54-5FDB-4605-949A-5C050C77C675Q38661071-13A753AA-26DB-418C-8777-003233290EE0Q38719576-9C5596AD-A8FF-4DA6-B40C-8ED1222DBB5FQ38746238-BCE56B1F-6043-4681-8E6F-D1111A5B5B53Q38827170-92BDE0C6-AC85-436B-9E70-C622B52D41E2Q38839079-BA4093A7-5F2E-48C3-A1FA-E0016C76ED14Q38854566-97A5FB13-92B0-4841-B5DB-AACDC6BCB72CQ38856794-CFB0C3C8-3D2C-4F92-93B3-B8498B1C273AQ38925121-DE4CD1FD-F579-4A02-ADF5-428B3B4C79ECQ38949089-F3A2D9E8-FD91-4CAA-A082-762D5C7CC358Q39107176-0988B507-FBCD-44E5-BF22-3CA1F21673D1
P2860
Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease
@ast
Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease
@en
type
label
Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease
@ast
Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease
@en
prefLabel
Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease
@ast
Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease
@en
P2093
P2860
P356
P1433
P1476
Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease
@en
P2093
Chadwick W Christine
Gabriele Mittermeyer
John Forsayeth
Kathryn H Rosenbluth
Krystof S Bankiewicz
Michael J Aminoff
Paul L Kaplan
Paul Larson
Philip Starr
Suzanne L Baker
P2860
P304
P356
10.1089/HUM.2011.220
P577
2012-04-10T00:00:00Z